Clinical Trials | December 29, 2025
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Subscribe To Our Newsletter & Stay Updated
